Orion Porfolio Solutions LLC Boosts Position in Boston Scientific Corporation $BSX

Orion Porfolio Solutions LLC raised its position in Boston Scientific Corporation (NYSE:BSX) by 60.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 58,486 shares of the medical equipment provider’s stock after acquiring an additional 21,936 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Boston Scientific were worth $5,710,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BSX. Steph & Co. bought a new position in shares of Boston Scientific in the 3rd quarter worth approximately $25,000. Financial Consulate Inc. purchased a new position in shares of Boston Scientific in the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the period. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter valued at approximately $26,000. Finally, United Community Bank raised its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Down 2.4%

Shares of BSX stock opened at $71.24 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a one year low of $70.75 and a one year high of $109.50. The company’s fifty day moving average price is $85.03 and its 200-day moving average price is $94.55. The company has a market capitalization of $105.71 billion, a price-to-earnings ratio of 36.72, a PEG ratio of 1.00 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the firm posted $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.50% of the stock is currently owned by company insiders.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Oppenheimer dropped their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. Canaccord Genuity Group lowered their target price on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. National Bank Financial set a $115.00 price target on Boston Scientific in a report on Monday, February 2nd. Finally, Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.